Skip to main content
Literatur
1.
Zurück zum Zitat Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 1998;21:256–60.CrossRefPubMed Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 1998;21:256–60.CrossRefPubMed
2.
Zurück zum Zitat Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.CrossRefPubMed Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.CrossRefPubMed
Metadaten
Titel
Agranulocytosis due to an α-glucosidase inhibitor, voglibose
verfasst von
Reo Yoshikawa
Ruka Hishinuma
Hiroshi Kaneko
Hidekatsu Yanai
Publikationsdatum
01.09.2015
Verlag
Springer India
Erschienen in
International Journal of Diabetes in Developing Countries / Ausgabe 3/2015
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-014-0242-7

Weitere Artikel der Ausgabe 3/2015

International Journal of Diabetes in Developing Countries 3/2015 Zur Ausgabe